Larynx preservation: what is the standard treatment?

Crit Rev Oncol Hematol. 2012 Dec:84 Suppl 1:e97-e105. doi: 10.1016/j.critrevonc.2010.11.008. Epub 2010 Dec 23.

Abstract

Locally advanced laryngeal and hypo-pharyngeal cancers have a rather poor prognosis. Up until the early 1990s, standard treatment was total laryngectomy, with dramatic functional and social outcome. The introduction of cisplatin based chemotherapy made concurrent chemo-radiotherapy (CCRT) the standard treatment for selected patients, fit for an organ preservation strategy. Over two decades of improvement in nonsurgical management of locally advanced laryngeal cancer is reviewed, including the most recent improvements with the introduction of taxanes and anti-EGFR targeted therapy.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / therapeutic use*
  • Bridged-Ring Compounds / therapeutic use*
  • Chemoradiotherapy / methods
  • ErbB Receptors / antagonists & inhibitors
  • ErbB Receptors / metabolism
  • Humans
  • Laryngeal Neoplasms / drug therapy*
  • Laryngeal Neoplasms / metabolism
  • Laryngeal Neoplasms / pathology
  • Laryngeal Neoplasms / radiotherapy*
  • Larynx / drug effects*
  • Larynx / metabolism
  • Larynx / pathology
  • Larynx / radiation effects*
  • Molecular Targeted Therapy / methods
  • Taxoids / therapeutic use*

Substances

  • Antineoplastic Agents
  • Bridged-Ring Compounds
  • Taxoids
  • taxane
  • ErbB Receptors